Stifel Canada Forecasts Weaker Earnings for HLS Therapeutics

HLS Therapeutics Inc. (TSE:HLS) – Equities research analysts at Stifel Canada decreased their FY2024 EPS estimates for HLS Therapeutics in a research report issued on Tuesday, November 12th. Stifel Canada analyst J. Keywood now expects that the company will earn ($0.88) per share for the year, down from their prior estimate of ($0.86). The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($0.31) EPS.

Separately, Stifel Nicolaus lowered their target price on HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

HLS Therapeutics Stock Performance

Shares of HLS Therapeutics stock opened at C$3.25 on Friday. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. The firm has a 50 day simple moving average of C$3.55 and a 200 day simple moving average of C$3.56. HLS Therapeutics has a fifty-two week low of C$3.00 and a fifty-two week high of C$5.48. The firm has a market cap of C$103.32 million, a P/E ratio of -3.22 and a beta of 1.07.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.